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Abstract: Globally, there is an uprising interest for availability of tangible, novel, added value, sustainable 
commercial exploitable therapeutic compounds from naturally derived sources. The paper will highlight bioactive 
compounds of therapeutic potential from marine sources such as polysaccharides, especially glycosaminoglycans. 
It is now well documented, and this effort combined with a green technological approach in sustainable natural 
biodiversity will allow the development of a new generation of therapeutics. Outsourcing for a biocompatible, 
non-mutational bioactive compound such as GAG’s in a worldwide research and industrial agenda. Hence, the 
thorough understanding on how the biosynthesis, structure and function of complex glycosaminoglycans will 
reveal the polysaccharides from the marine environment could provide a valid alternative to traditional 
polysaccharides such as glycosaminoglycans. 
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1. Introduction 
 
The oceans cover more than 70% of the world 
surface and between 36 known living phyla, 34 are 
taxonomied within the marine environments with more 
than 300000 odd known species of fauna and flora[1,2,3]. 
Per se, the biodiversity of the marine environment and 
its associated biological and chemical biodiversity 
constitute a tangible practically unlimited bioresource 
of new bioactive substances or in outsourcing of 
biocompounds in the field of the development and 
optimization of novel sustainable commercially 
exploitable bioactive marine based product[4,5].  
Marine organisms have been known from time 
immemorial to possess curative powers. But until 
recently, their bioactive compounds, nutraceutical 
properties, and green technology optimized commercial 
potential remained undiscovered. The marine world 
represents a largely untapped reservoir of bioactive 
ingredients that can be applied in numerous aspects of 
food processing, storage, and fortification. Thus, the 
marine environment is an exceptional reservoir of 
bioactive natural products, many of which exhibit 
structural or chemical features not scientifically 
evidence located within terrestrial natural products. 
These marine-derived functional ingredients are such as 
certain polysaccharides (sulfated or total), polyphenols, 
polyunsaturated fatty acids and carotenoids, which have 
been reported to have a definitive global role as 
nutraceutical in improving human health and 
nutrition[6]. 
Plants and terrestrial microorganisms (especially 
those from soil samples) are traditionally in the focus of 
the search for new drug candidates from nature (also 
called “bioprospecting”). Due to the repeated re-
isolation of already known compounds, the emphasis on 
the search for new drug-like chemical entities is 
nowadays shifting to less investigated organisms from 
unique habitats such as the sea[7,8]. So far, seven drugs 
derived from marine natural products are already 
registered either in the EU or in the US and many more 
are under clinical or preclinically investigated. 
The concept of nutraceutical has been derived by 
coining the terms "nutrition" and "pharmaceutical". In 
this context, active substances with pharmaceutical 
properties are delivered to the humans through food-
based approaches to prevent or treat certain disease 
conditions. Since the natural sources are recognized as 
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safe for human consumption, the active substances 
produced in the diverse group of marine organisms 
have a wider role in the nutraceutical industry. These 
marine-derived active ingredients include certain 
polysaccharides, polyphenols, bioactive peptides, 
polyunsaturated fatty acids, and carotenoids which are 
known to have anticancer, anti-inflammatory, 
antioxidant, anti-obesity, hypocholesterolemic, 
antimicrobial, prebiotic, and probiotic activity enabling 
them to be applied as nutraceutical. 
Marine organisms produce a rich variety of 
sulphated glycosaminoglycans with characteristic 
variations of sugar composition and sulphation patterns 
determined by the species of origin. The distinct 
molecular structures and biophysical properties of 
marine GAGs reflect the evolutionary adaptation and 
diversification of sulphated polysaccharides to complex 
and changing habitats. Marine GAGs are derived from 
organisms that have significant regenerative capacity. 
They may have interesting effects on the activities of 
many growth factors, morphogens etc. (for example 
FGF, HGF/SF, VEGF, GDNF) that are activated by 
Heparan Sulphate co-receptors. 
Marine eco-environment or biosphere represents 
tremendous flora and fauna biodiversity therapeutics 
exploitable tangibilities sources and original 
polysaccharides worth further in-depth optimization 
and investigation. However, these marine sources are 
very much species specific. However, the abundance 
and stable morphological characterization are an 
adjusted much sort of, as such this marine environment 
can provide a validated alternative to traditional or folk 
medicine. 
Taxonomized, elucidated design, optimized marine 
outsourced compounds can potentially be exploited for 
naturally derived drug discovery and for the delivery of 
better sustainable new marine-derived outsourced 
product for pharmaceutical and therapeutics application 
and efficacies.  
Among the various sources for the development of 
new drugs, compounds from living organisms, so-called 
natural products, are of particular significance[9]. 
Nowadays, approximately one third of today’s best 
selling drugs are either natural products or have been 
developed based on lead structures provided by 
nature[10]. 
Some literature have reviewed that over 14,000 
different natural products from marine organisms have 
been described[11], hundreds of patents describing new 
bioactive marine natural products have been filed[12]. 
Stated that various marine natural products are 
currently in clinical trials mostly in the areas of cancer, 
pain or inflammatory diseases.  
 
2. The present understanding about GAG   
 
Glycosaminoglycans (GAGs) which are sometimes 
known as mucopolysaccharides[13] are large, complex 
carbohydrate molecules that interact with a wide range 
of proteins involved in physiological and pathological 
processes[14,15]. There are two types of GAGs, sulfated 
GAGs and nonsulfated GAGs. GAGs can be sulfated 
(chondroitin sulfate, dermatan sulfate, heparin/heparan 
sulfate, keratin sulfate) or (hyaluronic acid). 
GAGs such as heparin, heparan sulfate (HS), and 
dermatan sulfate (DS) serve as key biological response 
modifiers by acting as:  
(1)  Stabilizers, cofactors, and co-receptors for growth 
factors, cytokines, and chemokines;  
(2)  Regulators of enzyme activity;  
(3)  Signaling molecules in response to cellular 
damage, such as wounding, infection, and 
tumorigenesis; and  
(4)  Targets for bacterial, viral, and parasitic virulence 
factors for attachment, invasion, and immune 
system evasion[16].  
Glycosaminoglycans are found in not only 
vertebrates but also many invertebrates, implying a 
conserved function in the animal kingdoms[17]. The 
presence of GAGs in various vertebrates, as well as 
invertebrates, has been well documented and increasing 
interest has been shown by different sectors such as 
research, biochemical industries, biopharmaceutical, 
nutraceutical and biomedical[18]. Glycosaminoglycans 
are the major component of the extracellular matrix 
molecules in animal tissues, play an important role in 
various physiological events[17].  
Glycosaminoglycans (GAGs) present in all 
animals: some of them such as heparin and dermatan 
sulfate are extracted from mammalian mucosa for 
therapeutical uses[19]. Table 1 below shows the 
therapeutic properties and potential modulated from 
marine sources which are from GAG, 
mucopolysaccharides and proteoglycan. 
 
Table 1. Therapeutic properties/potential modulated from some voucher specimen for marine sources (GAG / Mucopolysaccharides / 
Proteoglycan). 
 
Species Tissues Biological Properties / Potential References 
Sea-cucumber (S. Hermanni) Visceral Anti-inflammatory Siti Fathiah et al., 2011 
Fish (sharks, skate, codfish, salmon, and trout) Cartilages, ligament Antitumor, Anti-pathogenic International Patent Application, US 20070010430. 
Starfish (Crown-of-Thorns) Integument Antithrombotic,  
Anti-inflammatory 
Nur Afiqah et al., 2012 
Sponges (Porifera) Body wall Anti-pathogenic, Anticoagulant Zierer et al., 2000 
Mussels (Perna canaliculus) Integument Anti-inflammatory International Patent Application, US 
nr. AU 2002242861 
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3. Biomedical interests in GAG 
 
The exploration of the marine potential of what 
concerns the isolation of compounds and its further use 
and application in the biomedical field is still in its 
infancy. The number of naturally derived products 
continues to expand steadily in terms of number of 
compounds investigated, which has been closely 
followed by the increase of intellectual property, 
namely by the number of patents 
filled[20,21,22,23,24,25,26,27,28,29,30]. Still, to a large extent, the 
marine environment is regarded as a largely untapped 
source of chemical diversity[31]. In fact, the harvesting 
of marine potential is not limited to drug discovery 
alone. Although the main emphasis has been given to 
pharmaceuticals, other potential applications for 
marine-derived materials have been additionally 
explored. Among the wide variability of marine origin 
molecules, algae sulphated polysaccharides are of 
proven economical importance, demonstrated by their 
wide application in food industry and medicine and 
because they found no equivalent in terrestrial 
organisms[18]. 
 
4. Insight Biochemistry of GAGs 
 
From 1930 to 1960, great strides have been made 
in analyzing the chemistry of these polysaccharides 
preparations (also known as “mucopolysaccharides”), 
yielding the structure of hyaluronan, dermatan sulfate 
(DS), keratan sulfate (KS), different isomeric forms of 
chondroitin sulfate (CS), heparin and heparan sulfate 
(HS). Together, these polysaccharides came to be 
known as glycosaminoglycans (sometimes abbreviated 
as GAGs) to indicate the presence of amino sugars and 
other sugars in a polymeric form[32]. Table 2 shows 
repeating disaccharide units of various 
glycosaminoglycans (GAGs). 
Glycosaminoglycans are linear polysaccharides, 
whose disaccharide building blocks consist of an amino 
sugar (N-acetylglucosamine, glucosamine that is 
variously N-substituted, or N-acetylgalactosamine) and 
a uronic acid (glucuronic acid or iduronic acid) or 
galactose. Sulfated glycosaminoglycans can be 
covalently bound to a protein to form proteoglycans[19]. 
Proteoglycans consist of a core protein and one or more 
covalently attached glycosaminoglycan chains (Fig. 1). 
Proteoglycans consist of a protein core (brown) and 
one or more covalently attached glycosaminoglycan 
chains ([blue] HS; [yellow] CS/DS). Membrane 
proteoglycans either span the plasma membrane (type I 
membrane proteins) or are linked by a GPI anchor. 
ECM proteoglycans are usually secreted, but some 
proteoglycans can be proteolytically cleaved and shed 
from the cell surface[32]. 
Glycosaminoglycans consist of repeating 
disaccharide units composed of an N-acetylated or N-
sulfated hexosamine and either a uronic acid 
(glucuronic acid or iduronic acid) or galactose. 
Hyaluronan lacks sulfate groups, but the rest of the 
glycosaminoglycans contain sulfates at various 
positions. DS is distinguished from CS by the presence 
of iduronic acid. Keratan sulfates lack uronic acids and 
instead consist of sulfated galactose and N-
acetylglucosamine residues[32]. 
 
Table 2. Repeating disaccharide units of various GAGs. 
 
GAGs Disaccharide units 
Hyaluronan 
(HA) 
 
 
Chondroitin sulfate  
(CS) 
 
 
Dermatan sulfate  
(DS) 
 
 
Keratan sulfate 
(KS) 
 
 
Heparan sulfate 
(HS) or Heparin 
 
-N-sulpho-6-sulphoglucosaminyl-(l4)- 
iduronate 2-sulphate 
 
 
 
Fig. 1. Proteoglycans core protein and covalently attached 
glycosaminoglycan chains. 
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Fig. 2. Depicts characteristic features of the major types of 
glycosaminoglycans found in vertebrates. 
 
5. Bioactive complexes of GAG from marine 
species 
 
GAGs are biopolymers industrially extracted from 
various animal organs. There are patent applications, 
which disclose obtaining methods of some GAGs 
derivatives of heparinoids from bacteria Escherichia 
coli[33] or heparin and heparinoids from fish (carp, 
mackerel, cod, herring, anchovy, shark and salmon) and 
other marine organisms with anticoagulant and 
antithrombotic activity exclusively[34,35,36]. Another 
patent application discloses a pharmaceutical 
composition with anti-inflammatory properties, which 
contain sulfated hexosamines and a protein extract from 
Perna canaliculus[37]. Other inventors isolate GAGs 
from cartilaginous fish that present antitumor effect[38]. 
However, it seems that these products do not capitalize 
the whole therapeutic potential of the GAGs concerned. 
 
6. Dilemma of inland source GAGs  
 
There is an immense diversity of marine plants and 
animals from which an estimated 14,000 
pharmacologically active compounds have been 
isolated[39]. GAG has never been reported in plants. 
Reports also revealed structural diversity in vertebrate 
GAGs. Among the sulfated glycosaminoglycans, 
heparan sulfate, a ubiquitous cell surface component of 
mammals and other vertebrates, is the one that exhibits 
the highest structural variability according to the tissue 
and species of origin[40]. Table 3 shows a comparison of 
why GAG harvesting from inland or marine 
invertebrates sources is better considered[41]. 
 
7. GAGs from marine sources 
 
Among the various sources for the development of 
new drugs, compounds from living organisms, so-called 
natural products, are of particular significance[40]. The 
oceans cover more than 70% of the earth's surface and 
are an indispensable source of protein for human 
nutrition. With regard to drug discovery and 
development, however, the oceans started to attract 
interest from pharmaceutical companies and research 
institutions only approximately 50 years ago with the 
discovery of the sponge-derived nucleosides 
spongothymidine and spongouridine[42]. 
 
Table 3. Comparison table to illustrate why GAG harvesting from 
inland or marine invertebrates sources is considered better. 
 
Vertebrates / Inland Marine Invertebrates 
1. Heterogenous structure 1.  Homogenous structure 
2. Diverse sulfation pattern 2.  Sulfated total-, N-, and O- 
sulfated Glycosaminoglycans 
3. Mutational defects in most 
genes – biosynthetically 
derived enzyme which 
causes severe 
consequences. 
3.  Stable expansion of sulfated 
structures: Pharmacologically 
active compounds are  
associated to a hetero 
undescribed  compound 
(reaction of waste to benefit 
opportunities) 
4.  Risk for the presence of 
infections. 
4.  No alteration in structure 
(morphologically      
undefended) 
5. Can reliable of availability 
(cost, volume) restrict to 
certain use. 
5.  Originally species specific 
 
The presence of sulfated GAG in a diverse range of 
marine phyla-like sponges (Porifera)[43] and several 
classes of fishes (Actinopterygii and others), 
particularly in commercially relevant species like 
sharks, skate, codfish, salmon, and trout is being 
discussed. It is because, marine-derived GAGs are 
being extensively studied because of their 
pharmaceutical activities like anti-pathogenic, 
antitumor and anticoagulant and as new biomaterials 
with application in different areas such as biomedical, 
bioengineered biomaterials applications, tissue 
engineering and regenerative medicine research[18]. 
Results from some recent studies also suggest that 
echinoderms are a potential source of 
glycosaminoglycans (also known as 
mucopolysaccharides). These are especially effective in 
improving skin appearance, healing wounds and are 
also important for the healthy functioning of joints[44]. 
According to[45], better yield of sulfated GAGs has 
been successfully extracted from locally harvested 
Crown-of-thorns (A. planci) and in that quantitative 
studies conducted, it seems to suggest that a sustainable 
volume for production technology is achievable. The 
high content of GAGs from the wasted COT biomass 
can thus be a better tangible source of collagenous 
threads as compared with other outsourced 
Echinodermata mass. It is thus, evidently based proven 
that the locally harvested Crown of Thorns (COT) 
which is also a phylum echinoderm are of the potential 
tangible of GAGs source. 
Literature have shown that body’s coelomic fluid 
from COT’s contained the highest amount of total 
sulfated GAG, followed by body’s integument, arm’s 
internal tissue, arm’s integument, body’s internal tissue 
and the lowest amount was extracted from arm’s 
coelomic fluid[45]. 
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On the other hand, literature have been 
documented that sea cucumbers or ‘GAMAT’ can help 
cure certain ailments and diseases[46]. Sea cucumber and 
their products have long been purported as a source of 
traditional medicines due to their various important 
nutritional and medicinal values[47]. In addition, the 
coelomic fluid of certain sea cucumbers has been 
reported to contain high bioactive substances that 
suggest orchestrating an important role in wound 
healing[48].  
However, according to[49], the integument body 
wall of S. hermanni and S. vastus has the richest source 
of sulfated GAGs followed by the visceral internal 
organs and coelomic fluid. The data are congruent with 
nutrient analyses that showed the integument body wall 
and the visceral internal organs (especially intestines) 
part of sea cucumbers to have a much higher nutrient 
value of protein and lower in fat[50].  
Thus, based on the previous study conducted both 
by[45,49] it was objectively proved that (homogenous, 
non-adulterated, therapeutic) GAG can be derived from 
COT and sea cucumber biomass. Table 5 and 6 below, 
revealed that COT possessed more total sulfated GAGs 
content per milligram as compared with the sea 
cucumber. Although, GAGs have been isolated in other 
Echinoderms, especially the sea cucumber[51] however, 
there is poor scientific evidence and research’s to 
elucidate the presence of GAG in COT biomass 
especially from the local coastal region. Hence, GAG 
derived from COT biomass is still a scientific lacuna 
especially in determining its prowess as an alternative 
source, especially (from marine sources) for wound 
healing dynamics. Apart from that, it is also 
scientifically noted that the COT body region contained 
the highest amount of total sulfated GAG as compared 
to its arm, even though the internal tissue from the body 
is of low amount[45]. Table 4 shows the differences 
between marine species and its potential for 
commercialization. 
 
8. The Future for Marine outsource GAG 
 
The oceans are the source of a large group of 
structurally unique natural products that are mainly 
accumulated in invertebrates such as sponges, tunicates, 
bryozoans, and molluscs[52]. Marine polysaccharides 
present an enormous variety of structures. They are still 
underexploited and therefore they should be considered 
as an extraordinary source of chemical diversity for 
drug discovery[53]. Marine species offer a great diversity 
of polysaccharides showing interesting biological 
properties mimicking those described for the 
mammalian GAGs. Table 7 below summarizes the 
technical microscopical features related to “efficiency 
studies” observed in respect to GAG adulteration and 
its potential for the future used. 
 
Table 4. Differences in taxonomy, local geochemical signature and therapeutic value between marine species. 
 
 Starfish Sea cucumber Sandfish Golden Sandfish Small Fish 
Reference Nur Afiqah et al.,2011 Kariya et al.,1990 Natacha Agudo, 2006 Daniel Azari Beni Giraspy & Grisilda Ivy 
Natalia Rosoiu et al., 
2008 
Family Acanthasteridae Stichopodidae Holothuriidae Holothuriidae - 
Genus Acanthaster Apostichopus Holothuria Holothuria - 
Species A. planci, Linnaeus, 1758 A. japonicus H. scabra, Jaeger H. lessoni, Conand Engraulis encrasicolus ponticus 
Therapeutic value Positive bioactive compound 
from anatomical parts 
Sulfated Gag from body Food Delicacy Food Delicacy Positive biological active 
compound 
Temp. - 15-21ºC 27-30ºC 25-27ºC - 
Salinity - 27-35 ppt 28-36 ppt 37-38 ppt - 
Dissolved oxygen - > 5mg/L 5-6 mg/L >5.5mg/L - 
pH - 8.1-8.3 6-9 8.2 - 
 
Table 5. Percentage (%) division of O- and N-sulfated GAGs from Sea Cucumber [49]. 
 
Sea cucumber species Anatomical parts O-sulfated GAGs (%) N-sulfated GAGs (%) 
S. hermanni 
 
Integument body wall 
Visceral internal organs 
Coelomic fluid 
Integument body wall 
Visceral internal organs 
Coelomic fluid 
55.04 ± 2.55 
44.94 ± 12.37 
62.71 ± 12.8 
70.79 ± 7.45 
69.99 ± 11.68 
82.31 ± 6.7 
44.96 ± 2.6 
55.06 ± 12.4 
37.29 ± 12.8 
29.21 ± 7.5 
30.01 ± 11.7 
17.69 ± 6.7 
S. vastus 
 
Table 6. Percentage (%) division of N- and O-sulfated Glycosaminoglycans (GAGs) from COT[45]. 
 
Species Anatomical parts O-sulfated GAGs (%) N-sulfated GAGs (%) 
Acanthaster planci 
(Body) 
Integument body wall 17.06 ± 0.50 82.94 ± 0.50 
Internal tissue 20.00 ± 0.30 80.00 ± 0.30 
Coelomic fluid 
Integument body wall 
Internal tissue 
Coelomic fluid 
24.99 ± 2.25 
18.05 ± 0.75 
16.50 ± 0.14 
13.14 ± 0.80 
75.01 ± 2.25 
81.95 ± 0.75 
83.50 ± 0.14 
86.86 ±  0.80 
Acanthaster planci 
(Arms) 
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Table 7. Technical microscopical features in relation to “efficiency studies” observed to GAG adulteration. 
 
Novelty Process Microscopical features 
Engineered cell 
nuclear line 
model 
1) Tissue organization 
1) Collagen restoration binding 
2) Keratin deposition 
3) Mutagenesis or vascularization 
4) Polymorphonuclear infiltration 
5) Fibroblast proliferation 
 2) pH fluid (intracellular / extracellular) neutralization 1) Reconstruction of extracellular matrix / 
basement membrane 
Tissue therapy 
3)     -cell-matrix interaction 
        -osteogenesis 
        -monolayer cell proliferation 
 
1) Migration of endothelial cells 
 
9. Justification why local geochemical signatures 
such as sea cucumbers’ and COT are now being 
pursued and harvested for therapeutic efficacies 
 
To date, researchers have isolated approximately 
7000 marine natural products, 25 percent of which are 
from algae, 33 percent from sponges, 18 percent from 
coelenterates (sea whips, sea fans and soft corals), and 
24 percent from representatives of other invertebrate 
phyla such as ascidians (also called tunicates), 
opisthobranch molluscs (nudibranchs, sea hares etc.), 
echinoderms (starfish, sea cucumbers etc.) and 
bryozoans (moss animals). A simplistic analysis of 
these data reveals that as the search for “Drugs from the 
Sea” progresses at the rate of a 10 percent increase in 
new compounds per year, researchers are concentrating 
their efforts on slow-moving or sessile invertebrate 
phyla that have soft bodies, and the lack of spines or a 
shell, i.e. animals that require a chemical defense 
mechanism [54,5].  
A very different kind of substances has been 
obtained from marine organisms among other reasons 
because they are living in a very exigent, competitive, 
and aggressive geochemical signatures surrounding, 
very different in many aspects from the terrestrial 
environment, a situation that demands the production of 
quite specific and potent active molecules. As such, in 
an associated perspective, these compounds seem to be 
very useful and promising for biomedical research to 
clarify many normal and pathological mechanisms of 
action in the human body as well as in the design of 
very specific and potent new pharmaceuticals for a 
wide variety of diseases. In tandem with this, and with 
sustainable green technological approaches 
improvement of aquaculture, the potential of these 
marine microorganisms to be exploited for the 
obtainment of lead molecules is clearly immense as 
feasibility to cultivate in laboratory conditions also 
improves and the industrial biotechnological techniques 
to optimize and manipulate its variables from the initial 
sources of bioactive natural products excel. 
 
10. Conclusion 
 
This writes up hope to highlight and reveals that 
there is an acute need for developing new therapeutic 
bioproducts based on the optimized study that may 
allow improving the efficiency and therapies means of 
sulfated GAG. Both marine invertebrates (Crown-of-
thorns and Sea Cucumber) have shown positive effects 
as biocompound reactant. Encouraging results in animal 
studies and clinical trials will support the clinical 
relevance of these glycosaminoglycans based drugs and 
the use of glycosaminoglycans as therapeutic targets. 
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